Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/119047Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Santos, S | |
| dc.creator | Junqueira, M | |
| dc.creator | Francisco, G | |
| dc.creator | Vilanova, M | |
| dc.creator | Magalhães, A | |
| dc.creator | Baruffi, M | |
| dc.creator | Chammas, R | |
| dc.creator | Harris, A | |
| dc.creator | Reis, CA | |
| dc.creator | Bernardes, E | |
| dc.date.accessioned | 2019-02-21T12:16:25Z | - |
| dc.date.available | 2019-02-21T12:16:25Z | - |
| dc.date.issued | 2016 | |
| dc.identifier.issn | 1949-2553 | |
| dc.identifier.uri | https://hdl.handle.net/10216/119047 | - |
| dc.description.abstract | ST6GalNAc-I, the sialyltransferase responsible for sialyl-Tn (sTn) synthesis, has been previously reported to be positively associated with cancer aggressiveness. Here we describe a novel sTn-dependent mechanism for chemotherapeutic resistance. We show that sTn protects cancer cells against chemotherapeutic-induced cell death by decreasing the interaction of cell surface glycan receptors with galectin-3 and increasing its intracellular accumulation. Moreover, exogenously added galectin-3 potentiated the chemotherapeutics-induced cytotoxicity in sTn non-expressing cells, while sTn overexpressing cells were protected. We also found that the expression of sTn was associated with a reduction in galectin-3-binding sites in human gastric samples tumors. ST6GalNAc-I knockdown restored galectin-3-binding sites on the cell surface and chemotherapeutics sensibility. Our results clearly demonstrate that an interruption of O-glycans extension caused by ST6GalNAc-I enzymatic activity leads to tumor cells resistance to chemotherapeutic drugs, highlighting the need for the development of novel strategies to target galectin-3 and/or ST6GalNAc-I. | |
| dc.description.sponsorship | This work was supported by funding from the São Paulo Research Foundation (FAPESP grant number 2012/06875-6), the Coordination for the Improvement of Higher Education Personnel (CAPES). CR acknowledges IPATIMUP, which integrates the i3S Research Unit, which is partially supported by FCT, the Portuguese Foundation for Science and Technology. CR work is funded by FEDER funds through the Operational Programme for Competitiveness Factors-COMPETE and National Funds through the FCT, under the projects: PEst-C/SAU/ LA0003/2013, PTDC/BBB-EBI/0786/2012 PTDC/BBB-EBI/0567/2014 and GastricGlycoExplorer (grant number 316929). MDB acknowledges Conselho Nacional de Desenvolvimento Científico e Tecnológico [CNPq, grant numbers 467646/2014-7]. Also, the research leading to these results has received support and funding from the Núcleo de Apoio à Pesquisa em Doenças Inflamatórias [NAPDIN, grant number 11.1.21625.01.0]. ALH acknowledges the Cancer Research UK and the Breast Cancer Research Foundation. | |
| dc.language.iso | eng | |
| dc.publisher | Impact Journals | |
| dc.relation | info:eu-repo/grantAgreement/FCT/COMPETE/132983/PT | |
| dc.relation | info:eu-repo/grantAgreement/FCT/COMPETE/125428/PT | |
| dc.relation.ispartof | Oncotarget, vol.7(50), p. 83570-83587 | |
| dc.rights | openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/3.0/ | |
| dc.subject | Animals | |
| dc.subject | Antigens, Tumor-Associated, Carbohydrate/genetics | |
| dc.subject | Antigens, Tumor-Associated, Carbohydrate/metabolism | |
| dc.subject | Antineoplastic Agents/pharmacology | |
| dc.subject | Cell Line, Tumor | |
| dc.subject | Cell Proliferation | |
| dc.subject | Cisplatin/pharmacology | |
| dc.subject | Dose-Response Relationship, Drug | |
| dc.subject | Drug Resistance, Neoplasm | |
| dc.subject | Galectin 3/metabolism | |
| dc.subject | Glycosylation | |
| dc.subject | Humans | |
| dc.subject | Mice, Inbred BALB C | |
| dc.subject | Mice, Nude | |
| dc.subject | Protein Processing, Post-Translational | |
| dc.subject | Protein Transport | |
| dc.subject | RNA Interference | |
| dc.subject | Sialyltransferases/genetics | |
| dc.subject | Sialyltransferases/metabolism | |
| dc.subject | Stomach Neoplasms/drug therapy | |
| dc.subject | Stomach Neoplasms/genetics | |
| dc.subject | Stomach Neoplasms/metabolism | |
| dc.subject | Stomach Neoplasms/pathology | |
| dc.subject | Time Factors | |
| dc.subject | Transfection | |
| dc.subject | Tumor Burden | |
| dc.title | O-glycan sialylation alters galectin-3 subcellular localization and decreases chemotherapy sensitivity in gastric cancer | |
| dc.type | Artigo em Revista Científica Internacional | |
| dc.contributor.uporto | Instituto de Investigação e Inovação em Saúde | |
| dc.identifier.doi | 10.18632/oncotarget.13192 | |
| dc.relation.publisherversion | http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=13192&pubmed-linkout=1 | |
| Appears in Collections: | I3S - Artigo em Revista Científica Internacional | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Santos S et al., Oncotarget 2016.pdf | 2.28 MB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License
